{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T18:24:27Z","timestamp":1789842267882,"version":"4.0.1"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:00:00Z","timestamp":1708646400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:00:00Z","timestamp":1708646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100010441","name":"Medizinischen Fakult\u00e4t Heidelberg, Universit\u00e4t Heidelberg","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010441","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018936","name":"Universit\u00e4tsklinikum Heidelberg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018936","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s40262-024-01350-x","type":"journal-article","created":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T05:02:21Z","timestamp":1708664541000},"page":"469-481","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Time Course of the Interaction Between Oral Short-Term Ritonavir Therapy with Three Factor Xa Inhibitors and the Activity of CYP2D6, CYP2C19, and CYP3A4 in Healthy Volunteers"],"prefix":"10.1007","volume":"63","author":[{"given":"Brit S.","family":"Rohr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8636-7993","authenticated-orcid":false,"given":"Evelyn","family":"Krohmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8583-7181","authenticated-orcid":false,"given":"Kathrin I.","family":"Foerster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2190-1698","authenticated-orcid":false,"given":"J\u00fcrgen","family":"Burhenne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5876-7322","authenticated-orcid":false,"given":"Martin","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8743-5194","authenticated-orcid":false,"given":"Antje","family":"Blank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1783-133X","authenticated-orcid":false,"given":"Gerd","family":"Mikus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0672-6876","authenticated-orcid":false,"given":"Walter E.","family":"Haefeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,23]]},"reference":[{"issue":"5","key":"1350_CR1","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40265-022-01692-5","volume":"82","author":"YN Lamb","year":"2022","unstructured":"Lamb YN. Nirmatrelvir plus ritonavir: first approval. Drugs. 2022;82(5):585\u201391. https:\/\/doi.org\/10.1007\/s40265-022-01692-5.","journal-title":"Drugs"},{"issue":"10","key":"1350_CR2","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1007\/s00228-013-1530-8","volume":"69","author":"C Eichbaum","year":"2013","unstructured":"Eichbaum C, Cortese M, Blank A, Burhenne J, Mikus G. Concentration effect relationship of CYP3A inhibition by ritonavir in humans. Eur J Clin Pharmacol. 2013;69(10):1795\u2013800. https:\/\/doi.org\/10.1007\/s00228-013-1530-8.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"1350_CR3","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/jac\/dkh029","volume":"53","author":"RK Zeldin","year":"2004","unstructured":"Zeldin RK, Petruschke RA. Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. J Antimicrob Chemother. 2004;53(1):4\u20139. https:\/\/doi.org\/10.1093\/jac\/dkh029.","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"1350_CR4","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1345\/aph.1K615","volume":"42","author":"MM Foisy","year":"2008","unstructured":"Foisy MM, Yakiwchuk EM, Hughes CA. Induction effects of ritonavir: implications for drug interactions. Ann Pharmacother. 2008;42(7):1048\u201359. https:\/\/doi.org\/10.1345\/aph.1K615.","journal-title":"Ann Pharmacother"},{"issue":"1","key":"1350_CR5","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.tips.2009.10.001","volume":"31","author":"O Kis","year":"2010","unstructured":"Kis O, Robillard K, Chan GN, Bendayan R. The complexities of antiretroviral drug-drug interactions: role of ABC and SLC transporters. Trends Pharmacol Sci. 2010;31(1):22\u201335. https:\/\/doi.org\/10.1016\/j.tips.2009.10.001.","journal-title":"Trends Pharmacol Sci"},{"issue":"3","key":"1350_CR6","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1124\/dmd.115.067744","volume":"44","author":"LM Vermeer","year":"2016","unstructured":"Vermeer LM, Isringhausen CD, Ogilvie BW, Buckley DB. Evaluation of ketoconazole and its alternative clinical CYP3A4\/5 inhibitors as inhibitors of drug transporters: the in vitro effects of ketoconazole, ritonavir, clarithromycin, and itraconazole on 13 clinically-relevant drug transporters. Drug Metab Dispos. 2016;44(3):453\u20139. https:\/\/doi.org\/10.1124\/dmd.115.067744.","journal-title":"Drug Metab Dispos"},{"issue":"17","key":"1350_CR7","doi-asserted-by":"publisher","first-page":"9866","DOI":"10.3390\/ijms23179866","volume":"23","author":"NHC Loos","year":"2022","unstructured":"Loos NHC, Beijnen JH, Schinkel AH. The mechanism-based inactivation of CYP3A4 by ritonavir: what mechanism? Int J Mol Sci. 2022;23(17):9866. https:\/\/doi.org\/10.3390\/ijms23179866.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"1350_CR8","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/clpt.2011.164","volume":"90","author":"S Katzenmaier","year":"2011","unstructured":"Katzenmaier S, Markert C, Riedel KD, Burhenne J, Haefeli WE, Mikus G. Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using a limited sampling strategy. Clin Pharmacol Ther. 2011;90(5):666\u201373. https:\/\/doi.org\/10.1038\/clpt.2011.164.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"1350_CR9","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.tcm.2020.12.004","volume":"31","author":"MAM Ali","year":"2021","unstructured":"Ali MAM, Spinler SA. COVID-19 and thrombosis: from bench to bedside. Trends Cardiovasc Med. 2021;31(3):143\u201360. https:\/\/doi.org\/10.1016\/j.tcm.2020.12.004.","journal-title":"Trends Cardiovasc Med"},{"issue":"12","key":"1350_CR10","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1124\/dmd.112.046888","volume":"40","author":"MS Bathala","year":"2012","unstructured":"Bathala MS, Masumoto H, Oguma T, He L, Lowrie C, Mendell J. Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans. Drug Metab Dispos. 2012;40(12):2250\u20135. https:\/\/doi.org\/10.1124\/dmd.112.046888.","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"1350_CR11","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1124\/dmd.109.029694","volume":"38","author":"L Wang","year":"2010","unstructured":"Wang L, Zhang D, Raghavan N, Yao M, Ma L, Frost CE, et al. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos. 2010;38(3):448\u201358. https:\/\/doi.org\/10.1124\/dmd.109.029694.","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"1350_CR12","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1124\/dmd.108.025569","volume":"37","author":"C Weinz","year":"2009","unstructured":"Weinz C, Schwarz T, Kubitza D, Mueck W, Lang D. Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. Drug Metab Dispos. 2009;37(5):1056\u201364. https:\/\/doi.org\/10.1124\/dmd.108.025569.","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"1350_CR13","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1477-9560-11-10","volume":"11","author":"W Mueck","year":"2013","unstructured":"Mueck W, Schwers S, Stampfuss J. Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring. Thromb J. 2013;11(1):10. https:\/\/doi.org\/10.1186\/1477-9560-11-10.","journal-title":"Thromb J"},{"issue":"1","key":"1350_CR14","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s10557-020-07129-z","volume":"36","author":"T Zhao","year":"2022","unstructured":"Zhao T, Chen Y, Wang D, Wang L, Dong P, Zhao S, et al. Identifying the dominant contribution of human cytochrome P450 2J2 to the metabolism of rivaroxaban, an oral anticoagulant. Cardiovasc Drugs Ther. 2022;36(1):121\u20139. https:\/\/doi.org\/10.1007\/s10557-020-07129-z.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"9984","key":"1350_CR15","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1016\/s0140-6736(14)61943-7","volume":"385","author":"CT Ruff","year":"2015","unstructured":"Ruff CT, Giugliano RP, Braunwald E, Morrow DA, Murphy SA, Kuder JF, et al. Association between edoxaban dose, concentration, anti-factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet. 2015;385(9984):2288\u201395. https:\/\/doi.org\/10.1016\/s0140-6736(14)61943-7.","journal-title":"Lancet"},{"issue":"15","key":"1350_CR16","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1007\/s40265-019-01183-0","volume":"79","author":"MC Herink","year":"2019","unstructured":"Herink MC, Zhuo YF, Williams CD, DeLoughery TG. Clinical management of pharmacokinetic drug interactions with direct oral anticoagulants (DOACs). Drugs. 2019;79(15):1625\u201334. https:\/\/doi.org\/10.1007\/s40265-019-01183-0.","journal-title":"Drugs"},{"issue":"3","key":"1350_CR17","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/bcp.12075","volume":"76","author":"W Mueck","year":"2013","unstructured":"Mueck W, Kubitza D, Becka M. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br J Clin Pharmacol. 2013;76(3):455\u201366. https:\/\/doi.org\/10.1111\/bcp.12075.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"1350_CR18","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1111\/jth.14871","volume":"18","author":"S Testa","year":"2020","unstructured":"Testa S, Prandoni P, Paoletti O, Morandini R, Tala M, Dellanoce C, et al. Direct oral anticoagulant plasma levels\u2019 striking increase in severe COVID-19 respiratory syndrome patients treated with antiviral agents: the Cremona experience. J Thromb Haemost. 2020;18(6):1320\u20133. https:\/\/doi.org\/10.1111\/jth.14871.","journal-title":"J Thromb Haemost"},{"issue":"3","key":"1350_CR19","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1177\/08971900221074938","volume":"36","author":"V Lomakina","year":"2022","unstructured":"Lomakina V, Sozio SJ, Tekle J. Use of apixaban in atrial fibrillation with ritonavir-boosted antiretroviral therapy: a case report. J Pharm Pract. 2022;36(3):728\u201332. https:\/\/doi.org\/10.1177\/08971900221074938.","journal-title":"J Pharm Pract"},{"issue":"7","key":"1350_CR20","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1177\/0956462419832099","volume":"30","author":"SA Nisly","year":"2019","unstructured":"Nisly SA, Stevens BN. Ritonavir- or cobicistat-boosted antiretroviral therapy and direct oral anticoagulants: a case for apixaban. Int J STD AIDS. 2019;30(7):718\u201322. https:\/\/doi.org\/10.1177\/0956462419832099.","journal-title":"Int J STD AIDS"},{"issue":"1","key":"1350_CR21","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s40800-015-0014-4","volume":"2","author":"CE Corallo","year":"2015","unstructured":"Corallo CE, Grannell L, Tran H. Postoperative bleeding after administration of a single dose of rivaroxaban to a patient receiving antiretroviral therapy. Drug Saf Case Rep. 2015;2(1):11. https:\/\/doi.org\/10.1007\/s40800-015-0014-4.","journal-title":"Drug Saf Case Rep."},{"issue":"10","key":"1350_CR22","doi-asserted-by":"publisher","first-page":"e604","DOI":"10.1093\/cid\/ciaa284","volume":"71","author":"JM George","year":"2020","unstructured":"George JM, Kuriakose SS, Monroe A, Hou Q, Byrne M, Pau AK, et al. Utilization of direct oral anticoagulants in people living with human immunodeficiency virus: observational data from the District of Columbia cohort. Clin Infect Dis. 2020;71(10):e604\u201313. https:\/\/doi.org\/10.1093\/cid\/ciaa284.","journal-title":"Clin Infect Dis"},{"issue":"144","key":"1350_CR23","doi-asserted-by":"publisher","DOI":"10.4414\/smw.2014.13906","volume":"22","author":"B Lakatos","year":"2014","unstructured":"Lakatos B, Stoeckle M, Elzi L, Battegay M, Marzolini C. Gastrointestinal bleeding associated with rivaroxaban administration in a treated patient infected with human immunodeficiency virus. Swiss Med Wkly. 2014;22(144): w13906. https:\/\/doi.org\/10.4414\/smw.2014.13906.","journal-title":"Swiss Med Wkly"},{"key":"1350_CR24","unstructured":"European Medicines Agency. Summary of product characteristics Paxlovid. 2022. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/paxlovid-epar-product-information_en.pdf. Accessed 18 Sept 2023."},{"issue":"8","key":"1350_CR25","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1111\/bcp.14277","volume":"86","author":"G Mikus","year":"2020","unstructured":"Mikus G, Foerster KI, Schaumaeker M, Lehmann ML, Burhenne J, Haefeli WE. Application of a microdosed cocktail of 3 oral factor Xa inhibitors to study drug-drug interactions with different perpetrator drugs. Br J Clin Pharmacol. 2020;86(8):1632\u201341. https:\/\/doi.org\/10.1111\/bcp.14277.","journal-title":"Br J Clin Pharmacol"},{"key":"1350_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-023-07443-2","author":"A Lenard","year":"2023","unstructured":"Lenard A, Hermann SA, Stoll F, Burhenne J, Foerster KI, Mikus G, et al. Effect of clarithromycin, a strong CYP3A and P-glycoprotein inhibitor, on the pharmacokinetics of edoxaban in healthy volunteers and the evaluation of the drug interaction with other oral factor Xa inhibitors by a microdose cocktail approach. Cardiovasc Drugs Ther. 2023. https:\/\/doi.org\/10.1007\/s10557-023-07443-2.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"7","key":"1350_CR27","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s40262-020-00862-6","volume":"59","author":"M Vay","year":"2020","unstructured":"Vay M, Meyer MJ, Blank A, Skopp G, Rose P, Tzvetkov MV, et al. Oral yohimbine as a new probe drug to predict CYP2D6 activity: results of a fixed-sequence phase I trial. Clin Pharmacokinet. 2020;59(7):927\u201339. https:\/\/doi.org\/10.1007\/s40262-020-00862-6.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"1350_CR28","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s00228-022-03304-3","volume":"78","author":"A Elbe","year":"2022","unstructured":"Elbe A, Foerster KI, Blank A, Rose P, Burhenne J, Haefeli WE, et al. Evaluation of CYP2C19 activity using microdosed oral omeprazole in humans. Eur J Clin Pharmacol. 2022;78(6):975\u201387. https:\/\/doi.org\/10.1007\/s00228-022-03304-3.","journal-title":"Eur J Clin Pharmacol"},{"issue":"148","key":"1350_CR29","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.jpba.2017.10.011","volume":"30","author":"KI Foerster","year":"2018","unstructured":"Foerster KI, Huppertz A, Muller OJ, Rizos T, Tilemann L, Haefeli WE, et al. Simultaneous quantification of direct oral anticoagulants currently used in anticoagulation therapy. J Pharm Biomed Anal. 2018;30(148):238\u201344. https:\/\/doi.org\/10.1016\/j.jpba.2017.10.011.","journal-title":"J Pharm Biomed Anal"},{"issue":"7","key":"1350_CR30","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1007\/s00216-011-5675-y","volume":"402","author":"J Burhenne","year":"2012","unstructured":"Burhenne J, Halama B, Maurer M, Riedel KD, Hohmann N, Mikus G, et al. Quantification of femtomolar concentrations of the CYP3A substrate midazolam and its main metabolite 1\u2019-hydroxymidazolam in human plasma using ultra performance liquid chromatography coupled to tandem mass spectrometry. Anal Bioanal Chem. 2012;402(7):2439\u201350. https:\/\/doi.org\/10.1007\/s00216-011-5675-y.","journal-title":"Anal Bioanal Chem"},{"issue":"16","key":"1350_CR31","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.4155\/bio-2019-0129","volume":"11","author":"M Vay","year":"2019","unstructured":"Vay M, Sauter M, Mikus G, Burhenne J. Quantification of microdosed oral yohimbine and its major metabolite in human plasma in the picogram range. Bioanalysis. 2019;11(16):1459\u201367. https:\/\/doi.org\/10.4155\/bio-2019-0129.","journal-title":"Bioanalysis"},{"issue":"6","key":"1350_CR32","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/jcph.1789","volume":"61","author":"M Mahmoudi","year":"2021","unstructured":"Mahmoudi M, Foerster KI, Burhenne J, Weiss J, Mikus G, Haefeli WE. Application of microdosed intravenous omeprazole to determine hepatic CYP2C19 activity. J Clin Pharmacol. 2021;61(6):789\u201398. https:\/\/doi.org\/10.1002\/jcph.1789.","journal-title":"J Clin Pharmacol"},{"issue":"9","key":"1350_CR33","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1007\/s40262-019-00749-1","volume":"58","author":"G Mikus","year":"2019","unstructured":"Mikus G, Foerster KI, Schaumaeker M, Lehmann M-L, Burhenne J, Haefeli WE. Microdosed cocktail of three oral factor Xa inhibitors to evaluate drug-drug interactions with potential perpetrator drugs. Clin Pharmacokinet. 2019;58(9):1155\u201363. https:\/\/doi.org\/10.1007\/s40262-019-00749-1.","journal-title":"Clin Pharmacokinet"},{"key":"1350_CR34","unstructured":"Food and Drug Administration. Bioanalytical method validation guidance for industry. 2018. https:\/\/www.fda.gov\/files\/drugs\/published\/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf. Accessed 18 Sept 2023."},{"key":"1350_CR35","unstructured":"European Medical Agency. Guideline on bioanalytical method validation. 2012. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-bioanalytical-method-validation_en.pdf. Accessed 18 Sept 2023."},{"issue":"1","key":"1350_CR36","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s40262-021-01051-9","volume":"61","author":"BS Rohr","year":"2022","unstructured":"Rohr BS, Foerster KI, Blank A, Burhenne J, Mahmoudi M, Haefeli WE, et al. Perpetrator characteristics of azole antifungal drugs on three oral factor Xa inhibitors administered as a microdosed cocktail. Clin Pharmacokinet. 2022;61(1):97\u2013109. https:\/\/doi.org\/10.1007\/s40262-021-01051-9.","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"1350_CR37","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1007\/s00228-010-0878-2","volume":"66","author":"S Katzenmaier","year":"2010","unstructured":"Katzenmaier S, Markert C, Mikus G. Proposal of a new limited sampling strategy to predict CYP3A activity using a partial AUC of midazolam. Eur J Clin Pharmacol. 2010;66(11):1137\u201341. https:\/\/doi.org\/10.1007\/s00228-010-0878-2.","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"1350_CR38","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/clpt.2013.27","volume":"93","author":"B Halama","year":"2013","unstructured":"Halama B, Hohmann N, Burhenne J, Weiss J, Mikus G, Haefeli WE. A nanogram dose of the CYP3A probe substrate midazolam to evaluate drug interactions. Clin Pharmacol Ther. 2013;93(6):564\u201371. https:\/\/doi.org\/10.1038\/clpt.2013.27.","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"1350_CR39","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1111\/bcp.15720","volume":"89","author":"MH Breithaupt","year":"2023","unstructured":"Breithaupt MH, Krohmer E, Taylor L, K\u00f6rner E, Hoppe-Tichy T, Burhenne J, et al. Time course of CYP3A activity during and after metamizole (dipyrone) in healthy volunteers. Br J Clin Pharmacol. 2023;89(8):2458\u201364. https:\/\/doi.org\/10.1111\/bcp.15720.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"1350_CR40","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1002\/cpt.2687","volume":"112","author":"Z Wang","year":"2022","unstructured":"Wang Z, Chan ECY. Physiologically-based pharmacokinetic modeling-guided dose management of oral anticoagulants when initiating nirmatrelvir\/ritonavir (Paxlovid) for COVID-19 treatment. Clin Pharmacol Ther. 2022;112(4):803\u20137. https:\/\/doi.org\/10.1002\/cpt.2687.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"1350_CR41","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1002\/jcph.1784","volume":"61","author":"S Willmann","year":"2021","unstructured":"Willmann S, Coboeken K, Kapsa S, Thelen K, Mundhenke M, Fischer K, et al. Applications of physiologically based pharmacokinetic modeling of rivaroxaban-renal and hepatic impairment and drug\u2013drug interaction potential. J Clin Pharmacol. 2021;61(5):656\u201365. https:\/\/doi.org\/10.1002\/jcph.1784.","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"1350_CR42","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/17425255.2022.2074397","volume":"18","author":"S Hanigan","year":"2022","unstructured":"Hanigan S, Park JM. Evaluating pharmacokinetic drug-drug interactions of direct oral anticoagulants in patients with renal dysfunction. Expert Opin Drug Metab Toxicol. 2022;18(3):189\u2013202. https:\/\/doi.org\/10.1080\/17425255.2022.2074397.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1350_CR43","unstructured":"European Medicines Agency. Summary of product characteristics Xarelto\u00ae. 2018. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/xarelto. Accessed 18 Sept 2023."},{"issue":"8","key":"1350_CR44","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1111\/jth.14929","volume":"18","author":"AC Spyropoulos","year":"2020","unstructured":"Spyropoulos AC, Levy JH, Ageno W, Connors JM, Hunt BJ, Iba T, et al. Scientific and standardization committee communication: clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020;18(8):1859\u201365. https:\/\/doi.org\/10.1111\/jth.14929.","journal-title":"J Thromb Haemost"},{"issue":"7","key":"1350_CR45","doi-asserted-by":"publisher","first-page":"549","DOI":"10.5414\/cp201812","volume":"51","author":"J Stampfuss","year":"2013","unstructured":"Stampfuss J, Kubitza D, Becka M, Mueck W. The effect of food on the absorption and pharmacokinetics of rivaroxaban. Int J Clin Pharmacol Ther. 2013;51(7):549\u201361. https:\/\/doi.org\/10.5414\/cp201812.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"11","key":"1350_CR46","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1124\/dmd.119.086918","volume":"47","author":"EJY Cheong","year":"2019","unstructured":"Cheong EJY, Teo DWX, Chua DXY, Chan ECY. Systematic development and verification of a physiologically based pharmacokinetic model of rivaroxaban. Drug Metab Dispos. 2019;47(11):1291\u2013306. https:\/\/doi.org\/10.1124\/dmd.119.086918.","journal-title":"Drug Metab Dispos"},{"issue":"9","key":"1350_CR47","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.1016\/j.xphs.2017.04.044","volume":"106","author":"Y Tsuruya","year":"2017","unstructured":"Tsuruya Y, Nakanishi T, Komori H, Wang X, Ishiguro N, Kito T, et al. Different involvement of OAT in renal disposition of oral anticoagulants rivaroxaban, dabigatran, and apixaban. J Pharm Sci. 2017;106(9):2524\u201334. https:\/\/doi.org\/10.1016\/j.xphs.2017.04.044.","journal-title":"J Pharm Sci"},{"issue":"1","key":"1350_CR48","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.bcp.2014.06.020","volume":"91","author":"R Kaspera","year":"2014","unstructured":"Kaspera R, Kirby BJ, Sahele T, Collier AC, Kharasch ED, Unadkat JD, et al. Investigating the contribution of CYP2J2 to ritonavir metabolism in vitro and in vivo. Biochem Pharmacol. 2014;91(1):109\u201318. https:\/\/doi.org\/10.1016\/j.bcp.2014.06.020.","journal-title":"Biochem Pharmacol"},{"issue":"10","key":"1350_CR49","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1007\/s11095-020-02927-4","volume":"37","author":"JK Sodhi","year":"2020","unstructured":"Sodhi JK, Liu S, Benet LZ. Intestinal efflux transporters P-gp and BCRP are not clinically relevant in apixaban disposition. Pharm Res. 2020;37(10):208. https:\/\/doi.org\/10.1007\/s11095-020-02927-4.","journal-title":"Pharm Res"},{"issue":"6","key":"1350_CR50","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s40262-015-0342-7","volume":"55","author":"DA Parasrampuria","year":"2016","unstructured":"Parasrampuria DA, Truitt KE. Pharmacokinetics and pharmacodynamics of edoxaban, a non-vitamin K antagonist oral anticoagulant that inhibits clotting factor Xa. Clin Pharmacokinet. 2016;55(6):641\u201355. https:\/\/doi.org\/10.1007\/s40262-015-0342-7.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"1350_CR51","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1124\/dmd.113.054866","volume":"42","author":"T Mikkaichi","year":"2014","unstructured":"Mikkaichi T, Yoshigae Y, Masumoto H, Imaoka T, Rozehnal V, Fischer T, et al. Edoxaban transport via P-glycoprotein is a key factor for the drug\u2019s disposition. Drug Metab Dispos. 2014;42(4):520\u20138. https:\/\/doi.org\/10.1124\/dmd.113.054866.","journal-title":"Drug Metab Dispos"},{"issue":"597","key":"1350_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.120349","volume":"15","author":"T Kato","year":"2021","unstructured":"Kato T, Mikkaichi T, Yoshigae Y, Okudaira N, Shimizu T, Izumi T, et al. Quantitative analysis of an impact of P-glycoprotein on edoxaban\u2019s disposition using a human physiologically based pharmacokinetic (PBPK) model. Int J Pharm. 2021;15(597): 120349. https:\/\/doi.org\/10.1016\/j.ijpharm.2021.120349.","journal-title":"Int J Pharm"},{"issue":"11","key":"1350_CR53","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1111\/bcp.15835","volume":"89","author":"DS Cox","year":"2023","unstructured":"Cox DS, Rehman M, Khan T, Ginman K, Salageanu J, LaBadie RR, et al. Effects of nirmatrelvir\/ritonavir on midazolam and dabigatran pharmacokinetics in healthy participants. Br J Clin Pharmacol. 2023;89(11):3352\u201363. https:\/\/doi.org\/10.1111\/bcp.15835.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"1350_CR54","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1007\/s11095-011-0637-9","volume":"29","author":"JA Rhoades","year":"2012","unstructured":"Rhoades JA, Peterson YK, Zhu HJ, Appel DI, Peloquin CA, Markowitz JS. Prediction and in vitro evaluation of selected protease inhibitor antiviral drugs as inhibitors of carboxylesterase 1: a potential source of drug-drug interactions. Pharm Res. 2012;29(4):972\u201382. https:\/\/doi.org\/10.1007\/s11095-011-0637-9.","journal-title":"Pharm Res"},{"issue":"6","key":"1350_CR55","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.clpt.2005.09.001","volume":"78","author":"RE Aarnoutse","year":"2005","unstructured":"Aarnoutse RE, Kleinnijenhuis J, Koopmans PP, Touw DJ, Wieling J, Hekster YA, et al. Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers. Clin Pharmacol Ther. 2005;78(6):664\u201374. https:\/\/doi.org\/10.1016\/j.clpt.2005.09.001.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1350_CR56","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1097\/01.qai.0000219774.20174.64","volume":"42","author":"RF Yeh","year":"2006","unstructured":"Yeh RF, Gaver VE, Patterson KB, Rezk NL, Baxter-Meheux F, Blake MJ, et al. Lopinavir\/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J Acquir Immune Defic Syndr. 2006;42(1):52\u201360. https:\/\/doi.org\/10.1097\/01.qai.0000219774.20174.64.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"2","key":"1350_CR57","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1002\/jcph.798","volume":"57","author":"L Zhu","year":"2017","unstructured":"Zhu L, Bruggemann RJ, Uy J, Colbers A, Hruska MW, Chung E, et al. CYP2C19 genotype-dependent pharmacokinetic drug interaction between voriconazole and ritonavir-boosted atazanavir in healthy subjects. J Clin Pharmacol. 2017;57(2):235\u201346. https:\/\/doi.org\/10.1002\/jcph.798.","journal-title":"J Clin Pharmacol"},{"issue":"10","key":"1350_CR58","doi-asserted-by":"publisher","first-page":"3617","DOI":"10.1128\/aac.00526-07","volume":"51","author":"P Liu","year":"2007","unstructured":"Liu P, Foster G, Gandelman K, LaBadie RR, Allison MJ, Gutierrez MJ, et al. Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects. Antimicrob Agents Chemother. 2007;51(10):3617\u201326. https:\/\/doi.org\/10.1128\/aac.00526-07.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"1350_CR59","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s40262-016-0416-1","volume":"55","author":"N Hohmann","year":"2016","unstructured":"Hohmann N, Kocheise F, Carls A, Burhenne J, Weiss J, Haefeli WE, et al. Dose-dependent bioavailability and CYP3A inhibition contribute to non-linear pharmacokinetics of voriconazole. Clin Pharmacokinet. 2016;55(12):1535\u201345. https:\/\/doi.org\/10.1007\/s40262-016-0416-1.","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"1350_CR60","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1111\/bcp.13297","volume":"83","author":"N Hohmann","year":"2017","unstructured":"Hohmann N, Kreuter R, Blank A, Weiss J, Burhenne J, Haefeli WE, et al. Autoinhibitory properties of the parent but not of the N-oxide metabolite contribute to infusion rate-dependent voriconazole pharmacokinetics. Br J Clin Pharmacol. 2017;83(9):1954\u201365. https:\/\/doi.org\/10.1111\/bcp.13297.","journal-title":"Br J Clin Pharmacol"},{"key":"1350_CR61","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2147\/cpaa.S41999","volume":"5","author":"VV Upreti","year":"2013","unstructured":"Upreti VV, Song Y, Wang J, Byon W, Boyd RA, Pursley JM, et al. Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor. Clin Pharmacol. 2013;5:59\u201366. https:\/\/doi.org\/10.2147\/cpaa.S41999.","journal-title":"Clin Pharmacol"},{"issue":"5","key":"1350_CR62","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1177\/0091270006286904","volume":"46","author":"D Kubitza","year":"2006","unstructured":"Kubitza D, Becka M, Zuehlsdorf M, Mueck W. Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59\u20137939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol. 2006;46(5):549\u201358. https:\/\/doi.org\/10.1177\/0091270006286904.","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"1350_CR63","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1097\/FJC.0b013e31822f6c2b","volume":"58","author":"KT Moore","year":"2011","unstructured":"Moore KT, Plotnikov AN, Thyssen A, Vaccaro N, Ariyawansa J, Burton PB. Effect of multiple doses of omeprazole on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban. J Cardiovasc Pharmacol. 2011;58(6):581\u20138. https:\/\/doi.org\/10.1097\/FJC.0b013e31822f6c2b.","journal-title":"J Cardiovasc Pharmacol"},{"key":"1350_CR64","unstructured":"Mendell J, Lasseter K, Shi M. Effect of esomeprazole on edoxaban pharmacokinetics and pharmacodynamics when administered orally as tablet and as solution. Europace. 2011;13(Suppl 3). (Abstract P1052)."},{"issue":"4","key":"1350_CR65","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1097\/FJC.0b013e31826265b6","volume":"60","author":"J Mendell","year":"2012","unstructured":"Mendell J, Noveck RJ, Shi M. Pharmacokinetics of the direct factor Xa inhibitor edoxaban and digoxin administered alone and in combination. J Cardiovasc Pharmacol. 2012;60(4):335\u201341. https:\/\/doi.org\/10.1097\/FJC.0b013e31826265b6.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"Suppl 1","key":"1350_CR66","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/bph.16106","volume":"180","author":"BS Rohr","year":"2023","unstructured":"Rohr BS, Krohmer E, Mikus G, Foerster KI, Burhenne J, Schulz M, Blank A, Haefeli WE. Factor Xa inhibitors exposure increases by five-day, low-dose ritonavir therapy. Br J Pharmacol. 2023;180(Suppl 1):214. https:\/\/doi.org\/10.1111\/bph.16106. (Abstract OC108).","journal-title":"Br J Pharmacol"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-024-01350-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-024-01350-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-024-01350-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T09:11:34Z","timestamp":1714122694000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-024-01350-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,23]]},"references-count":66,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["1350"],"URL":"https:\/\/doi.org\/10.1007\/s40262-024-01350-x","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,23]]},"assertion":[{"value":"29 January 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open Access funding enabled and organized by Projekt DEAL. This trial was funded by the Department\u2019s internal resources. No medical writing support was used.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Walter E. Haefeli received grants for clinical trials, travel support, and lecture fees from Daiichi Sankyo, the manufacturer of edoxaban, not related to this work. All other authors have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The collected and analysed data can be made available upon reasonable request. Part of the data was presented at the 19th World Congress of Clinical Pharmacology, Glasgow, and therefore published as an abstract [].","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"The trial protocol (EudraCT 2021-006634-39) was approved by the competent authority (BfArM, Bonn, Germany) and the responsible Ethics Committee of the Medical Faculty of Heidelberg University. All procedures performed in studies involving human participants were in accordance with Good Clinical Practice (ICH-GCP) guidelines, all pertinent German laws, and the ethical standards specified in the applicable version of the declaration of Helsinki. All volunteers gave their written informed consent prior to any study procedures.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and informed consent"}},{"value":"The trial was registered at the European Union Drug Regulating Authorities for Clinical Trials (EudraCT-No. 2021-006643-39) and at German Clinical Trial Register with ID DRKS00027838.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Trial registration"}},{"value":"WEH and GM proposed the research topic. BSR, AB, EK, WEH, and GM developed the trial protocol. BSR was the responsible study physician and executed the trial. KIF and JB analysed the samples. BSR and GM performed the trial analysis and the statistics. BSR wrote the first draft of the manuscript. All authors discussed and interpreted the results and contributed to the manuscript.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}